In general, these results illustrate that DAXX inhibition, independent of ATRX, disrupts GBM-PDX oncogenic properties selectively in a PTEN-deficient genetic background, in part through downregulation of transcription factors that preserve glioma proliferation and upregulation of tumour suppressor genes. This evidence concerns the gene PTEN and neoplasm.